Literature DB >> 2711332

Biological effectiveness of neutrons and pi-mesons in gut, bone, and transplantable tumours.

J Kummermehr1, H Schraube, G Ries, L Köster, K H Höver, H Blattmann, P Stas, G Burger.   

Abstract

At the Munich RENT-facility a screening project was performed to define the biological characteristics of a fission neutron beam envisaged for radiotherapy. The quantitative endpoints used were jejunal crypt survival, late rectal stenosis in rats, osseous healing in traumatized rat femur and regrowth delay of murine transplantable tumours. The results obtained in normal tissues (with the possible exception of bone) demonstrate a high RBE, in accordance with the well documented dependence of RBE on neutron energy. The RBE-values measured in tumours after single dose treatment endorsed the high effectiveness, although--as has been the case with other beams--they gave no conclusive evidence of a therapeutic advantage. Nevertheless, the specific beam characteristics, i.e. a high RBE at the surface and a fast decline of the biologically effective depth dose suggest possible advantages of the RENT beam when applied in the treatment of selected superficial tumours.

Entities:  

Mesh:

Year:  1989        PMID: 2711332

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  2 in total

1.  Oxygen tension in transplanted mouse osteosarcomas during fractionated high-LET- and low-LET radiotherapy--predictive aspects for choosing beam quality?

Authors:  T Auberger; B Thürriegl; T Freude; L Weissfloch; R Senekowitsch-Schmidke; P Kneschaurek; F M Wagner; M Molls
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

2.  The Munich Fission Neutron Therapy Facility MEDAPP at the research reactor FRM II.

Authors:  Franz M Wagner; Peter Kneschaurek; Anton Kastenmüller; Birgit Loeper-Kabasakal; Severin Kampfer; Harald Breitkreutz; Wolfgang Waschkowski; Michael Molls; Winfried Petry
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.